Mitchell S.V. Elkind, M.D., American Heart Association president-elect, Chair of the Advisory Committee of the American Stroke Association — a division of the American Heart Association, and professor of neurology and epidemiology at Columbia University in New York, responds to questions from stroke survivors about COVID-19 on April 1, 2020.
Corresponding author Valentin Fuster (Mount Sinai Heart, New York, USA) and colleagues report in the Journal of the American College of Cardiology that hospitalised COVID-19 patients treated with anticoagulants had improved outcomes both in and out of the intensive care unit setting.
Developers are using artificial intelligence to help researchers comb through thousands of studies and find relevant COVID-19 information for the development of potential treatments and vaccines.
In cities hit hardest by COVID-19, another perplexing problem has emerged: younger patients who test positive for the virus are presenting to hospital with large-vessel strokes and—in some cases—no traditional stroke risk factors.
Carotid endarterectomy is a very common vascular surgical procedure done to prevent strokes in high-risk patients. Surgical approaches have been tested and improved over the years to ensure high technical success, and set the standard for low morbidity and mortality.
Final results from the UNTOUCHED study of the Emblem Subcutaneous Implantable Defibrillator (S-ICD) System were presented at Heart Rhythm Society (HRS) 2020 Science virtual meeting.
Pacemakers or implanted cardiac defibrillators that were retrieved postmortem, resterilized and reused in underserved countries conferred similar rates of infection and device-related deaths as new devices implanted in Canada.
Despite concerns expressed by some experts, common high blood pressure drugs did not increase the risk of contracting COVID-19 – or of developing severe disease – in a study of 12,594 patients.
The coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients.
The world is facing an unprecedented modern pandemic that has posed many new challenges to healthcare providers.
Vascular Solutions, Inc. has announced it is recalling the Langston Dual Lumen Catheter in response to reports that the inner catheter may separate during use. The US Food and Drug Administration has deemed it a Class I device recall, the most serious type.
Stay Up-To-Date on jobs and industry news.
Sign up for the CathLab.com newsletter today!